I N RECENT YEARS, numerous publications have appeared emphasizing the usefulness of mephentermine during various forms of anesthesia as a means of maintaining an adequate blood-pressure level. 1 " 3 Lundy 4 has employed mephentermine successfully as an effective antidote against narcotic drugs. Pharmacological studies of sympathomimetic drugs on pulmonary circulation have shown mephentermine to be a pulmonary vasodilator. 5 The object of the present study was to investigate the respiratory effects of mephentermine systematically, and to test in humans the cardiovascular actions of this drug on the pulmonary circulation, in view of the scant information existing at present on these actions in man.
Methods The present study comprised two groups of patients.
Chronic Pulmonary Disease Group
This group included 14 patients, 12 of whom were suffering from chronic pulmonary emphysema with varying degrees of fihrosis. The remaining two patients had asthma. Complete spirometrical studies were performed in 11 of these patients, both in the semireeumbent and sitting-up positions, at rest, and were repeated after intramuscular administration of 23 mg. of mephentermine (total). Average body surface in this group was 1.63 M. 2 . Immediately after these studies were completed, an aerosol with a known bronehodilator (cyclopentamine) was given and the maximum breathing capacity was determined when its bronehodilator effects were considered to be maximal. A Collins 9-L. respirometer without valves was used for these studies. Within the next 4S hours, a Cournand needle was inserted in the radial arteries of the 14 patients and left in place during a suitable stabilizing period. A control sample of a fiveminute respiration was collected in a Douglas bag, measured in a Precision Wet Test Meter and discarded. When conditions of the patient were considered basal, an arterial-blood sample was obtained under anaerobic conditions, while the patient inspired room air through a Collins J-valve. Expired air was collected in a Douglas bag during a five-to six-minute period. The number of respirations was recorded in a timed kymograph. The difference between the control sample of ventilation and the ventilation obtained simultaneously with an arterial-blood sample ranged between 0.22 and 0.90 L. per minute. The same procedure was repeated 25 minutes after intramuscular injection of 23 mg. of mephentermine (total). These same studies were carried out in three "hospital normal" controls.
Arterial blood was analyzed for C0 2 , 0 2 , and blood hemoglobin O 2 carrying capacity in the Van Slyke manoinetric apparatus. 6 Arterial-blood pH was determined at room temperature and corrected to 37 C. with the Beckman GS pH meter. 7 Arterial p c o was obtained with the Singer and Hastings nomogram. 8 Expired air was analyzed in the micro-Scholander apparatus, 9 and physiological dead space determined using the Bohr formula, 10 assuming arterial p co to be identical with alveolar p c o , and corrected by subtracting the dead space of the equipment.
Mitral Stenosis Group
This group included 25 patients suffering from mitral stenosis with varying degrees of pulmonary hypertension. Three of these patients had undergone mitral commissurotomy 8 to 12 months previously, but at the time of the present study, they had residual pulmonary hypertension and were included in this group. The patients were studied at rest and 25 to 30 minutes after administration of mephentermine during a right-heart catheterization. A placebo was given before mephentermine in approximately one-third of the patients. In nine cases, 23 mg. of mephentermine was administered intramuscularly, while in the remaining 16 cases, the drug was given by continuous intravenous drip at the rate of 0.017 mg./Kg./min. The average body surface in the nine patients in whom the drug was used intramuscularly was 1.43 M. 2 . The description of the technique followed has been published. 11 The results have been studied statistically by means of Student's i-test.
In a control group of three "normals," eatheterization was carried out in a similar manner; mephentermine was given intramuscularly in two eases and by continuous intravenous drip in one. The "normal" group consisted of two cases of patent ductus arteriosus and one atrial septal defect, 8 to 14 months after successful corrective surgery. Pressures in the pulmonary circulation were normal pre-and postoperatively. Clinical and hemodynamic studies were normal in this group.
Results Normal Controls
The results of spirometrical, pulmonaryventilation, and arterial-blood studies are contained in figure 1 and tables 1 and 2.
Expiratory minute volume and frequency of respiration increased in all cases. Alveolar ventilation went up in four cases and oxygen consumption rose in five of six cases; however, tidal-volume changes were negligible. Both CO2 tension and content in arterial blood decreased in four cases, while CO2 elimination increased in four and physiological dead space decreased in four cases. The physiological dead space/tidal volume ratio decreased in three cases, while arterial-blood saturation decreased in five eases.
The circulatory effects obtained in the three normal controls during right-heart catheterization are reported in figure 2 .
Cardiac output and work of the left and right ventricles increased in all three cases. Arteriolar pulmonary resistance and arteriovenous O2 difference decreased in every case. Heart rate, pressure in the pulmonary and systemic circuits, and total pulmonary-artery resistance changes were variable.
Chronic Pulmonary Disease Group Spirometry
Maximum breathing capacity increased after mephentermine administration and a further increase occurred after eyclopentamine aerosol given immediately after termination of spirometry in the first six cases (table 1). Insignificant increases occurred in the last five cases with mephentermine or aerosol.
It may be assumed that in patients with emphysema, whose maximum breathing capacity remains unchanged after eyelopentamine aerosol, a functionally irreversible airway obstruction is present. This frequently repre- •Column (1) represents the result of the 11 cases presented in table 1. t i n Column (2), the patients with functionally irreversible airway obstructions have been eliminated (the last five cases). sents permanent peribronchial anatomical fibrosis. There is a decrease in vital capacity, an increase in the "two-step" vital capacity, and a small increase in both expiratory reserve volume and inspiratory capacity (table 2, column 1). If cases in which aerosol administration produced no significant increase in maximum breathing capacity are dropped, then the effects of mephentermine become a moderate increase in maximum breathing capacity and a more pronounced drop in vital capacity (table 2, column 2).
Pulmonary-Ventilation
and Arterial-Blood Studies (Table S) There was a small increase in expiratory minute volume and alveolar ventilation, a decrease in physiological dead space and physiological dead space/tidal volume ratio, CO 2 Circulation Research, Volume IX, November 1961 tension and content in arterial blood, and an increase in frequency of respiration. The changes observed in tidal volume, O2 consumption, CO 2 elimination, respiratory quotient, O2 uptake, and CO2 removal per liter ventilation were negligible. Xone of these changes was statistically significant.
Mitral Stenosis Group

Pulmonary-Ventilation and Arterial-Blood Studies
No significant difference was found whether the drug was used intramuscularly or by continuous intravenous drip. There was a pronounced increase in expiratory minute volume and alveolar ventilation. In the intramuscular group, one case of nine had a slight decrease in expiratory minute volume and alveolar ventilation. In the intravenous series, 2 of 16 cases had small drops in expiratory min-
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.RADIALART. MEAN PRES. ute volume, and one had a slight reduction of alveolar ventilation. In this last series of cases, a very large increase in pulmonary ventilation was obtained in one patient. Expiratory minute volume increased from 6.07 L./ min. at rest to 15.30 L./min. after mephenterm i ne, while alveolar ventilation increased from 3.01 L./min. to 10.80 L./min. In this case, CO 2 content in arterial blood fell from 47.97 volumes per cent to 32.05; pco, dropped from 35.0 to 25.0 mm. Hg, and pH increased from 7.36 to 7.43. If this case were omitted from the statistical studies, the observed increase in expiratory minute volume and alveolar ventilation would become significant.
Figure 2 Schematic representation of cardiovascular changes in three normal controls after mephentermine. Dots represent two cases in which the drug was used intramuscularly during right-heart catheterization, and X represents one case in which it was used by continuous intravenous drip at
Frequency of respiration was significantly increased, with negligible changes in tidal volume. Physiological dead space and physiological dead space/tidal volume ratio were decreased. There was a significant decrease in CO2 content and tension in arterial blood, a significant increase in 0 2 consumption and CO 2 elimination, and in arterial-blood pH. Arterial-blood saturation changes were small and insignificant. Oxygen uptake and COremoval per liter ventilation showed minimal and insignificant changes.
Circulatory Studies (Table 4) The results obtained were similar when the drug was used intramuscularly or by continuous intravenous drip. Cardiac output increased, pulmonary-artery pressure decreased, pulse rate increased significantly, and wedge pressure increased in intramuscular cases, while it decreased very slightly in intravenous cases. Pulmonary resistances were decreased; total systemic resistance decreased in intramuscular cases, while it remained almost unchanged in intravenous cases. Systemic pressures and work of both ventricles were increased. Right-atrial pressures decreased in all but one case. All cases with abnormally high right-atrial pressure in the control period were reduced after mephentermine.
Discussion
The increase in maximum breathing capacity in emphysema eases after mephentermine demonstrates that mephentermine partly reverses existing bronchospasm. This interpretation is based on the observation that no increase in maximum breathing capacity occurred in normal controls or in patients in whom cyelopentamine also failed to produce a significant change. The fact that a further increase in maximum breathing capacity obtained when cyelopentamine aerosol was used after mephentermine indicates that mephentermine action did not relieve the existing bronchospasm completely.
Maximum breathing capacity depends on many factors. The changes observed in these patients with bronchospasm after mephentermine and/or cyclopentainine are unlikely to be due to an increase in the muscular force available, or to neuromuscular coordination of respiration. They are interpreted as being due to a decrease in the resistance to air flow through the traeheobronchial tree.
It is generally accepted that relief of bronchospasm determines an increase in maximum breathing capacity and in vital capacity. In this series, the "two-step" vital capacity increased while the vital capacity decreased. This was observed both in the semirecumbent and sitting-up positions. The discrepancy between the "two-step" vital capacity obtained from the sum of the inspiratory capacity and the expiratory reserve volume and that of the vital capacity recorded as a single measurement indicates air trapping. Increased air trapping after mephentermine may be due to the partial relief of airway obstruction in nonventilated or poorly ventilated pulmonaiy areas.
Mephentermine increased pulmonary ventilation markedly in normal controls and in mitral stenosis, in contrast to the minimal increases obtained in emphysema patients. This is particularly apparent when comparison is made between the emphysema patients and the mitral stenosis group, in whom the drug was used by the same intramuscular route and in the same total dose. The inerease in expiratory minute volume was brought about by a significant increase in frequency of respiration, -with small variable changes in either direction in tidal volume. Increases in tidal volume were frequently associated with corresponding increases in physiological dead space in mitral stenosis. The increased ventilation determined a reduction in both CO2 content and tension in arterial blood, and these changes led to a significant increase in arterial-blood pll. While the changes were minimal in emphysema patients, they were in the same direction. The difference in degree of response may be related to different pulmonary pathology in each disease, or to the relatively smaller dose per Kg. given to the chronic pulmonary disease group. Average body surface in this group was 1.63 M. 2 , while the average body surface in the mitral stenosis group in which it was used intramuscularly was only 1.43 M. 2 .
The CO2 and pH changes in arterial blood cannot explain the hyperventilation observed. Both hypocapnia and alkalosis are known inhibitors of respiration; consequently, the statistically significant increase in O2 consumption and C0 2 production cannot be the cause of the increased ventilation through a mechanism of increased C0 2 tension and content in arterial blood. Both CO2 tension and content were decreased and arterial blood pH was increased at the time the increased ventilation was measured. Particularly striking in some normal controls and in mitral stenosis cases was the decrease in arterial-blood Pco. associated with hyperventilation.
A bronchodilator action of mephentermine [NGUEZ and its vascular effects improving the ventilation-perfusion relationships, and thereby decreasing the physiological dead space, could determine an increase in alveolar ventilation. However, such a mechanism would produce a consistent reduction of the physiological dead space and physiological dead space/tidal volume ratio, with or without an increase in expiratory minute volume or frequency of respiration, as has been shown to occur with xanthines. 11 ' 12 Physiological dead space was reduced in 4 of 6 normals, in 8 of 14 emphysema cases, and in 10 of 20 mitral stenosis patients. Physiological dead space/tidal volume ratio was reduced in 3 of 6 normalsinsignificantly in emphysema, but significantly in mitral stenosis. These changes, as well as those observed in both directions in arterial-blood saturation, 13 are consistent with some peripheral drug action on ventilationperfusion relationships.
It appears probable that mephentermine acts on the respiratory center producing hyperventilation. A central action on the vasomotor center, as well as a central excitatory effect, have been described as being due to this drug. 14 " 10 The disproportionate increase in expiratory minute volume and frequency of respiration, in contrast with its moderate bronchiolar and circulatory effects, suggests a central action. A central stimulating action of mephentermine would satisfactorily explain the consistent hyperventilation and polypnea which results in a reduction in CO 2 content and tension in arterial blood and an increase in arterial-blood pH. When primary, these factors are known inhibitors of pulmonary ventilation. The fact that no important hyperventilation was observed in emphysema may be due to the relatively smaller dose employed, or may be related to altered mechanics of breathing existing in this disease, which would partly overcome the effects of central stimulation. The possibility that the respiratory center in emphysema is less sensitive to CO 2 than in normals or in mitral stenosis appears less likely, since only four cases of 14 had hypercapnia at rest.
The significant increase in 0 2 consumption and CO2 elimination in mitral stenosis and in five of the normal controls is noteworthy. Others have shown that mephentermine increases myocardial O2 consumption 17 and cerebral O2 consumption. 18 This action is similar to that of other sympathomimetic amines. In this study, the increase in Oo consumption cannot be accounted for by the significant increase in heart rate alone, 19 but may be due, at least in part, to the myocardial effects or the action on other organs of mephentermine. The grossly linear correlation between the percentage increase in expiratory minute volume and the percentage increase in O2 consumption suggests that the increase in 0 2 consumption is due to the increased work of the respiratory muscles ( fig. 3) . In pulmonary emphysema, where no significant increase in expiratory minute volume occurred, there was no significant increase in 0 2 consumption. Table 4 Mephentermine significant!}' increased the heart rate in mitral stenosis and in two of three normal controls. This effect of the drug has been previously described in dogs with BARRERA, REGALADO, CHANGSUT, DOMINGUEZ A-V DIFF. isolated supported hearts, and in dogs in which the vagi have been cut. 17 In our cases, direct myocardial actions of mephentermine appear to predominate over those of reflex origin which occur in the intact dog 17 and in humans. 20 Additional evidence of direct myocardial effects of mephentermine is the statistically significant reduction in right-atrial pressure, previously demonstrated in the dog 17 and the increase in cardiac output. 5 -21 In the present study, cardiac output increased in all three normal controls (mean increase 22.6 per cent) and in the majority of mitral stenosis cases. It should be noted that in the nine eases in which the drug was used intramuscularly, the mean increase was 17.7 per cent, while in the intravenous series, the mean increase was one-half this amount. Although this difference is not statistically significant, it may be explained b}' the difference in heart rate observed in both groups. While mean increases in heart rate in the intramuscular group amounted to 6.8 per cent, the intravenous group showed a mean increase of 14.9 per cent. It is well established in severe mitral stenosis that increases in heart rate will reduce cardiac output; consequently, in our cases, the increase in cardiac output due to myocardial drug action would be limited by the associated increase in heart rate (fig. 4) .
Circulatory Effects (Mitral Stenosis),
The effects on pulmonary-artery pressure were variable. The average mean pressure was insignificantly reduced after the drug. Increases in pulmonary-artery pressure, attributed to increased cardiac output, occurred in two normals, in three intramuscular-and five intravenous-administration cases of mitral stenosis. Increases in cardiac output associated with decreases in pulmonary-artery pressure were present in one normal, two intramuscular-and four intravenous-administration cases of mitral stenosis. Pulmonary vascular resistance was obviously decreased in this last group. A passive reduction of pulmonary vascular resistance associated with increased cardiac output cannot, of course, be eliminated. 22 Previous work 5 indicates that mephentermine increases cardiac output and dilates pulmonary arteries. Our limited information on three normal controls is in agreement with this finding. Cardiac output increased and pulmonary arteriolar resistance decreased in all cases. With the limitations encountered in mitral stenosis, mephentermine lowered arteriolar resistance in most cases (13 of 19 in which it was determined). Particularly in the intramuscular series, where changes in heart rate were less conspicuous and cardiac-output changes appeared more pronounced, mean wedge pressure increased, as should be expected of a drug dilating pulmonary arterioles in mitral stenosis. 23 In the intravenous group, results were probably complicated by the marked increase in heart rate. However, mean changes in wedge pressure showed a minimal decrease, associated with a more pronounced drop in arteriolar pulmonary resistance.
With few exceptions, systemic blood pressure rose as a result of mephentermine. Total systemic resistance decreased in the normals and in the intramuscular group, while in 10 of the 16 intravenous cases, it was reduced or remained approximately the same. These re- suits are interpreted as peripheral vasodilatation and are consistent with the findings of others. 14 -17 The fact that systemic resistance was moderately decreased or remained essentially unchanged in our cases indicates that local vasodilatation in some areas, such as has been shown to exist in animal experiments in the femoral distribution and in the coronary bed, 17 must be compensated by local vasoconstriction in other areas. This would explain the arteriovenous O 2 differences obtained during catheterization, which represent an integration of tissue O 2 extraction and, indirectly, of capillary circulation as a whole. Increased blood flow through an area with dilated vessels leads to a decreased arteriovenous difference and, thus, a marked increase in cardiac output. However, opposite compensatory effects, vasoconstriction with slower flow, will produce an increase in arteriovenous difference with a decrease in cardiac output, as observed in some of our cases, even those whose 0 2 consumption increased significantly ( fig. 5 ).
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Consequently, it appears that peripheral action of mephentermine in mitral stenosis is of importance in the determination of cardiac output. Increased cardiac output in normal controls and in patients with mitral stenosis is brought about both by myocardial stimulation, producing a better emptying of the ventricles through an increase in the myocardial contractile force, 21 and by peripheral factors supplying an adequate venous return. Decreased peripheral blood flow severely limits the response of the heart, in spite of a significant myocardial action.
Summary
Mephentermine increased maximum breathing capacity in emphysema patients due to partial relief of existing bronehospasm. Small variations occurred in tidal volume, arterialblood saturation, O 2 uptake and C0 2 removal per liter ventilation, and in respiratory quotient. There was an increase in expiratory minute volume, alveolar ventilation, frequency of respiration, O 2 consumption, C0 2 elimination, and arterial-blood pH; a decrease oc-curred in physiological dead space, physiological dead space/tidal volume ratio, and COo content and tension in arterial blood. These changes were marked in normal individuals and in mitral stenosis patients, in contrast to the minimal effects obtained in emphysema cases. Bronehodilatation in emphysema, reduction of the physiological dead space and physiological dead space/tidal volume ratio, and changes in both direction in arterial-blood saturation as well as circulatory effects suggest that mephentermine affects the ventilation-perfusion relationships throughout the lung. The disproportionate increase in expiratory minute volume and frequency of respiration, while arterial-blood findings showed a significant decrease in CO 2 tension and a significant increase in pH, suggests an important central effect. In normal and in mitral stenosis patients, mephentermine produced an increase in heart rate, a decrease in mean right-atrial pressure, and an increase in cardiac output as a result of myocardial stimulation. Changes in pulmonary-artery pressure were variable. Pulmonary arteriolar resistance decreased in all three normal controls and in the majority of mitral stenosis cases, while wedge pressure changed very slightly. These changes are interpreted as pulmonary vasodilatation. Systemic pressure increased, while total systemic resistance decreased or remained essentially unchanged. Arteriovenous O 2 difference decreased in most eases with increased cardiac output, and vice versa. Increased cardiac output, associated with unchanged or falling systemic resistances and decreased arteriovenous O2 difference, suggests vasodilatation with increased peripheral blood flow. The fact that systemic resistance increases slightly in some cases must mean that vasoconstriction with decreased peripheral blood flow occurred in other vascular areas as a probable compensatory reaction. These effects led to an increase in arteriovenous O 2 difference and a reduction in cardiac output.
